Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Peri-operative sintilimab + SOX versus SOX in locally advanced resectable gastric cancer
ChiCTR2100046711Phase 2Recruiting
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Jul 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of sintilimab in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma (2 arms), sponsored by Tianjin Medical University Cancer Institute and Hospital. Primary endpoint: pathological complete response rate. Started Jul 2021; status: recruiting.
02
Drugs
sintilimab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2100046711.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100046711.